Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT01087580 2017-03-03

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00598858 2016-12-08

2007-5904

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00041171 2016-07-12

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Phase 3 Withdrawn

BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT01071928 2015-08-19

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT01907308 2014-04-29

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01478308 2013-03-06

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00811031 2012-07-30

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

Clinical Trials

HARMONY

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

2007-5904

Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)